First Turn Management LLC Buys Shares of 88,714 Repligen Co. (NASDAQ:RGEN)

First Turn Management LLC purchased a new position in Repligen Co. (NASDAQ:RGEN - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 88,714 shares of the biotechnology company's stock, valued at approximately $13,202,000. Repligen comprises 2.1% of First Turn Management LLC's portfolio, making the stock its 29th biggest holding. First Turn Management LLC owned approximately 0.16% of Repligen as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of RGEN. Vanguard Group Inc. lifted its holdings in shares of Repligen by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company's stock valued at $937,994,000 after buying an additional 21,719 shares during the last quarter. Bank of New York Mellon Corp grew its position in Repligen by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company's stock worth $172,749,000 after acquiring an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in shares of Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company's stock worth $119,363,000 after purchasing an additional 199,322 shares during the last quarter. Thrivent Financial for Lutherans increased its stake in shares of Repligen by 6.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company's stock worth $95,037,000 after purchasing an additional 36,773 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in shares of Repligen by 14.4% in the 3rd quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company's stock valued at $84,387,000 after purchasing an additional 71,274 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RGEN has been the subject of several analyst reports. UBS Group reduced their target price on Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a report on Wednesday, July 31st. Benchmark restated a "hold" rating on shares of Repligen in a research report on Monday, August 5th. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research report on Wednesday, November 13th. JPMorgan Chase & Co. lifted their target price on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 31st. Finally, Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They issued a "peer perform" rating for the company. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $190.25.

Repligen Price Performance

NASDAQ:RGEN traded up $5.08 during trading hours on Tuesday, reaching $128.49. The company had a trading volume of 963,091 shares, compared to its average volume of 668,961. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The stock has a 50-day moving average of $140.67 and a two-hundred day moving average of $143.94. Repligen Co. has a one year low of $113.50 and a one year high of $211.13. The firm has a market capitalization of $7.20 billion, a PE ratio of -347.26, a PEG ratio of 3.75 and a beta of 0.96.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The business had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same quarter in the prior year, the firm earned $0.23 EPS. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. Analysts forecast that Repligen Co. will post 1.52 earnings per share for the current year.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.20% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.